These elite Houston researchers were named among the most-cited in their fields

MVPs

Houston is home to many talented researchers — and about 60 have been recognized by a global study for being among the most cited individuals in their fields. Photo via Getty Images

Nearly 60 scientists and professors from Houston-area universities and institutions, working in fields from ecology to immunology, have been named among the most-cited researchers in the world.

The Clarivate Highly Cited Researchers 2022 list considers a global pool of public academic papers that rank in the top 1 percent of citations for field and publication year in the Web of Science. It then ranks researchers by the number of times their work has been cited, or referenced, by other researchers, which, according to the University of Houston, helps their findings "become more impactful and gain further credibility."

This year 6,938 researchers from 70 different countries were named to this list. About 38 percent of the researchers are based in the U.S.

“Research fuels the race for knowledge and it is important that nations and institutions celebrate the individuals who drive the wheel of innovation. The Highly Cited Researchers list identifies and celebrates exceptional individual researchers who are having a significant impact on the research community as evidenced by the rate at which their work is being cited by their peers," says David Pendlebury, head of research analysis at the Institute for Scientific Information at Clarivate, in a statement. "These individuals are helping to transform human ingenuity into our world’s greatest breakthroughs.”

Harvard University was home to the most researchers, with 233 researchers making the list, far outpacing Stanford University, which had the second highest total of 126 researchers.

Texas universities and institutions had a strong showing, too. The University of Texas at Austin had 31 researchers on the list, tying UT with the University of Minnesota and Peking University in China for the No. 35 spot. MD Anderson had 30 researchers on the list, the most among organizations in Houston, earning it a 38th place ranking, tied with the University of Maryland and University of Michigan.

Below is a list of the Houston-area highly cited researchers and their fields.

From UT MD Anderson Cancer Center

  • Jaffer Ajani (Cross-Field)
  • James P. Allison (Immunology)
  • Jan A. Burger (Clinical Medicine)
  • George Calin (Cross-Field)
  • Jorge Cortes (Clinical Medicine)
  • Courtney DiNardo (Clinical Medicine)
  • John V. Heymach (Clinical Medicine)
  • David Hong (Cross-Field)
  • Gabriel N. Hortobagyi (Cross-Field)
  • Robert R. Jenq (Cross-Field)
  • Hagop M.Kantarjian (Clinical Medicine)
  • Marina Y. Konopleva (Clinical Medicine)
  • Dimitrios P. Kontoyiannis (Cross-Field)
  • Scott E. Kopetz (Clinical Medicine)
  • Alexander J. Lazar (Cross-Field)
  • J. Jack Lee (Cross-Field)
  • Anirban Maitra (Clinical Medicine)
  • Robert Z. Orlowski (Clinical Medicine)
  • Padmanee Sharma (Clinical Medicine and Molecular Biology and Genetics)
  • Anil K. Good (Cross-Field)
  • Jennifer A. Wargo (Molecular Biology and Genetics)
  • William G. Wierda (Clinical Medicine)

From Baylor College of Medicine

  • Erez Lieberman Aiden (Cross-Field)
  • Nadim J. Ajami (Cross-Field)
  • Christie M. Ballantyne (Clinical Medicine)
  • Malcolm K. Brenner (Cross-Field)
  • Hashem B. El-Serag (Clinical Medicine)
  • Richard Gibbs (Cross-Field)
  • Heslop, Helen Cross-Field
  • Joseph Jankovic (Cross-Field)
  • Sheldon L. Kaplan (Immunology)
  • Joseph F. Petrosino (Cross-Field)
  • Cliona Rooney (Cross-Field)
  • James Versalovic (Cross-Field)
  • Bing Zhang (Cross-Field)

From Rice University

  • Plucker M. Ajayan (Materials Science)
  • Pedro J. J. Alvarez (Environment and Ecology)
  • Naomi Halas (Materials Science)
  • Jun Lou (Materials Science)
  • Antonios G. Nikos (Cross-Field)
  • Aditya D. Mohite (Cross-Field)
  • Peter Nordlander (Materials Science)
  • Ramamoorthy Ramesh (Physics)
  • James M. Tour (Materials Science)
  • Robert Vajtai (Materials Science)
  • Haotian Wang (Chemistry)
  • Zhen-Yu Wu (Cross-Field)

From University of Houston

  • Jiming Bao (Cross-Field)
  • Shuo Chen (Cross-Field)
  • Whiffing Ren (Cross-Field)
  • Zhu Han (Computer Science)

From UTMB Galveston

  • Vineet D.Menachery (Microbiology)
  • Nikos Vasilakis (Cross-Field
  • Scott C. Weaver (Cross-Field)
  • From UT Health Science Center-Houston
  • Eric Boerwinkle (Cross-Field)
This new program is geared at preparing leaders at the intersection of health care and business. Image courtesy of Rice

New program launches in Houston to educate health care leaders

Two Houston institutions have teamed up to create a health care leadership program to prepare the next generation of life science executives.

Rice Business and The University of Texas MD Anderson Cancer Center have launched the Executive Leadership in Healthcare program at Rice University’s Jones Graduate School of Business. The new program will provide an opportunity for both current and emerging health care leaders across the country to learn from faculty and leaders in medicine in the Texas Medical Center.

“In executive education, we have been supporting the development of healthcare leaders for over 20 years — it has been a fascinating journey,” says Brent Smith, senior associate dean of executive education at Rice Business, in a news release. “We have learned so much about the challenges of leading institutions in such a dynamic and challenging industry and developed deep healthcare expertise. Our collaboration with MD Anderson allows our two institutions to blend our disciplinary expertise in healthcare strategy, leadership, operations and finance.”

The program is planned for two installments next year — over 10 days ion Feb. 6-10 and April 24-28. Participants will discover themselves as leaders and learn the business tools they need to become more impactful and effective within their organizations.

“We are excited to work with our colleagues at Rice Business to provide a thriving and unique learning platform for healthcare executives to navigate the complex environments they are facing,” says Courtney Holladay, associate vice president of the Leadership Institute at MD Anderson, in the release. “We believe MD Anderson’s senior leadership and Rice Business’ faculty provide complementary expertise and perspectives on both the practice and theory of leading healthcare institutions that will benefit participants.”

Those interested can learn more about the course online. Tuition is listed as $18,500.

“Staying connected to the business community and meeting the professional development needs of organizations both large and small are important to us,” says Michael Koenig, associate dean for innovation initiatives and executive director of executive education at Rice Business, in the release. “We’re excited about this initiative with MD Anderson and look forward to the impact our joint program will have on healthcare leaders and their institutions.”

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva made the striking discovery. Photo by Jeff Fitlow

Rice and MD Anderson researchers discover exciting new leukemia treatment

big win

Rice University and MD Anderson researchers have just discovered a potential one-two punch that could, they hope, knock out an insidious disease.

A recent study in the journal Leukemia centers on potential new drugs that, with the help of other medications, can thwart leukemia cells.

Specifically, Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva screened some 45,000 small-molecule compounds to find a few that targeted mitochondria, according to Rice press materials.

In this innovative new study, the team selected eight of the most promising compounds, identified between five and 30 closely related analogs for each, and conducted tens of thousands of tests to systematically determine how toxic each analog was to leukemia cells. This was measured both when administered individually or in combination with existing chemotherapy drugs like doxorubicin, notes a release.

Previously, Kirienko’s lab had shown the eight compounds targeted energy-producing machinery inside cells called mitochondria. Mitochondria, which work nonstop in every living cell, wear out with use. The chosen eight compounds induce mitophagy, which can be described as how cells decommission and recycle deficient and used-up.

Notably, during times of extreme stress, cells can temporarily forgo mitophagy for an emergency energy boost. Previous research has shown leukemia cells have far more damaged mitochondria than healthy cells and are also more sensitive to mitochondrial damage than healthy cells.

Thus, Kirienko and Konopleva reasoned that mitophagy-inducing drugs might weaken leukemia cells and make them more susceptible to chemotherapy. Synergy — using two or more drugs in treatment — is key.

“The point of synergy is that there are concentrations, or dosages, where a single drug doesn't kill,” Kirienko said. “There is no death of healthy cells or cancer cells. But administering those same concentrations in combination can kill a considerable amount of cancer cells and still not affect healthy cells.”

The team tested the toxicity of its mitophagy-inducing compounds and combinations against acute myeloid leukemia (AML) cells, the most commonly diagnosed form of the disease. They then tested the six most effective AML-killing compounds against other forms of leukemia, finding that five were also effective at killing acute lymphoblastic leukemia (ALL) cells and chronic myelogenous leukemia (CML) cells.

Studies found all the mitophagy-inducing drugs caused far less harm to healthy cells.

Finally, the researchers tested one of the most effective mitochondria-targeting compounds, PS127E, using a cutting-edge technique called a patient-derived xenograft (PDX) model. Also referred to as a “mouse clinical trial,” mice are implanted with cancer cells from a leukemia patient. As the cells grow, the mouse is exposed to a drug or combination of drugs as a closer-than-cells test of the treatment’s effect.

Importantly, PDX tests on one compound, PS127E, showed it was effective at killing AML cells in mice, Rice notes, signaling promising news.

“Although this is very promising, we’re still some distance from having a new treatment we can use in the clinic,” Kirienko added. “We still have a lot to discover. For example, we need to better understand how the drugs work in cells. We need to refine the dose we think would be best, and perhaps most importantly, we need to test on a wide variety of AML cancers. AML has a lot of variations, and we need to know which patients are most likely to benefit from this treatment and which are not. Only after we’ve done that work, which may take a few years, would we be able to start testing in humans.”

------

This article originally ran on CultureMap.

These cancer research professionals just got fresh funding from a statewide organization. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Texas nonprofit cancer research funder doles out millions to health professionals moving to Houston

money moves

Thanks in part to multimillion-dollar grants from the Cancer Prevention and Research Institute of Texas, two top-flight cancer researchers are taking key positions at Houston’s Baylor College of Medicine.

Dr. Pavan Reddy and Dr. Michael Taylor each recently received a grant of $6 million from the Cancer Prevention and Research Institute of Texas (CPRIT).

Reddy is leaving his position as chief of hematology-oncology and deputy director at the University of Michigan’s Rogel Cancer Center to become director of the Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center. Dr. C. Kent Osborne stepped down as the center’s director in 2020; Dr. Helen Heslop has been the interim director.

Taylor, a pediatric neurosurgeon at the University of Toronto, is set to become the first-ever director of pediatric neuro-oncology research at Texas Children’s Hospital. The hospital is affiliated with the Baylor College of Medicine. Taylor is an expert in children’s brain tumors.

In all, 11 researchers recruited by three health care institutions in Houston recently received $34 million in CPRIT grants. The nine other grant recipients in Houston are:

  • Dr. Christine Lovly, M.D. Anderson Cancer Center, $4 million. She is co-leader of the Translational Research and Interventional Oncology Research Program at the Vanderbilt-Ingram Cancer Center in Nashville.
  • Hans Renata, Rice University, $4 million. He is an associate professor at UF Scripps Biomedical Research in Jupiter, Florida.
  • Mingjie Dai, Rice University, $2 million. He is a technology development fellow at Harvard University’s Weiss Institute for Biologically Inspired Engineering.
  • William Hudson, Baylor College of Medicine, $2 million. He is a postdoctoral fellow at Emory University in Atlanta.
  • Deepshika Ramanan, M.D. Anderson Cancer Center, $2 million. She is a research fellow in immunology at Harvard Medical School.
  • Jason Schenkel, M.D. Anderson Cancer Center, $2 million. He is an instructor in pathology at Harvard’s Brigham and Women’s Hospital.
  • Aria Vaishnavi, M.D. Anderson Cancer Center, $2 million. She is a postdoctoral scholar at the University of Utah’s Huntsman Cancer Institute.
  • Samantha Yruegas, Rice University, $2 million. She is a postdoctoral research associate at Princeton University in New Jersey.
  • Qian Zhu, Baylor College of Medicine, $2 million. He is a research fellow at Harvard’s Dana-Farber Cancer Institute.

A CPRIT committee recently approved 17 recruitment grants totaling nearly $48 million for cancer research institutions in Texas.

“CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention … . These 17 highly respected researchers will join an impressive roster of cancer-fighters who call the Lone Star State home,” says Wayne Roberts, CEO of CPRIT.

Since its creation, CPRIT has awarded $2.9 billion in grants to cancer research organizations around the state.

A Houston-based biotech startup has fresh funds to continue R&D on its products. Photo via Getty Images

Houston biotech company raises $15M round led by Chinese health care investor

fresh funds

A Houston-based biotech company that was founded by a University of Texas MD Anderson Cancer Center doctor has closed a fresh round of funding.

Cellenkos closed its $15 million series A round led by BVCF Management, based in Shanghai, China. The biotech company is developing novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders. Dr. Simrit Parmar of the University of Texas MD Anderson Cancer Center and Golden Meditech Holdings Limited founded the company.

Dr. Parmar's specialty is in Lymphoma Myeloma and experimental therapeutics. According to a news release, she is also the principal investigator of a research laboratory focused on umbilical cord blood-derived Treg cells including their isolation and ex-vivo expansion for generating clinically relevant doses for their application in autoimmune diseases and inflammatory disorders.

"We feel fortunate to welcome BVCF as a new investor. As I look ahead, we are committed to bringing our novel Treg cell therapies to patients in need around the world," says Dr. Parmar in a news release.

BVCF is a health care investment firm focused on growth-stage healthcare companies from around the world. The portfolio has a particular focus on innovative solutions that address unmet health needs in China.

"Cellenkos' innovative and transformative Treg cell therapy platform to address autoimmune and inflammatory disorders has the potential to significantly serve unmet patient needs. We are proud to lead the financing and support their groundbreaking efforts," says Dr. Zhi Yang, managing partner at BVCF, in the release.

The company has plans to launch a phase 1b trial of add on therapy with one of its products for the treatment of myelofibrosis patients. The fresh funds will allow the company to continue to scale and test its life-saving technology.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

10+ can't-miss Houston business and innovation events for April

where to be

It's time to look at what's on the agenda for April for Houston innovators — from pitch competitions to networking events.

Here's a roundup of events not to miss this month. Mark your calendars and register accordingly.

Note: This post might be updated to add more events.

April 4 — A.I. Digital and the Future of Energy

In the latest installment of UH Energy's "Critical Issues in Energy" Symposium Series, the speakers will take a deeper dive into the role of A.l. within the energy marketplace, specifically with what is being done with A.I. and what is capable of being done. In addition to this pivotal look at one crucial aspect of the energy transition, attendees will be afforded networking opportunities with speakers and distinguished guests, and food/refreshments will be provided.

The event is Tuesday, April 4, from 5:30 to 7:30 pm, at the University of Houston. Click here to register.

April 5 — Creating & Sustaining Innovation & Entrepreneurship

Join us for a fireside chat discussing the growth of entrepreneurship & a panel on demystifying the patent process.

The event is Wednesday, April 5, from 9 to 11:30 am, at the Ion. Click here to register.

April 5 — HAN Angel Academy

Learn angel investing best practices from Capital Factory co-founder and chairman, Gordon Daugherty in a half-day bootcamp format for accredited investors.

The event is Wednesday, April 5, from 11 am to 4 pm, at Rice University - Shell Auditorium. Click here to register.

April 11 — Future of Health Care

The Greater Houston Partnership's inaugural Future of Health Care event highlights one of the region's major industry sectors driven by world-class institutions and professional talent.

The event is Wednesday, April 11, from 10:30 am to 1:30 pm, at the Royal Sonesta. Click here to register.

April 11 — Idea to Impact: Navigating the Challenges to Commercializing University Discoveries

Amazing discoveries are made in university labs every day, yet most of them never develop into widely accessible commercial products. Why? And what can universities do to change that? As part of Rice University's "Betterment of the World" Scientia Lecture Series, join Rice Business on April 11 at 4 pm virtually or in person (Shell Auditorium, McNair Hall) to hear Yael Hochberg, Professor in Entrepreneurship at the Jones Graduate School of Business, as she discusses the challenges in commercializing university research discoveries.

The event is Wednesday, April 11, from 4 to 5 pm, at Rice University and online. Click here to register.

April 11 — Greentown Houston Climatetech Career Fair 2023

Greentown Labs and ALLY Energy welcomes all professionals, students, and soon-to-be graduates to join us for the Greentown Houston Career Fair, which focuses on connecting professionals directly with Greentown Houston’ network of founders, CEOs, and cutting-edge climatetech startups looking for bright and eager talent.

The event is Tuesday, April 11, from 4:30 to 6:30 pm, at Greentown Houston. Click here to register.

April 15 — Earth Day Clothing Swap Party with Sustainable Fashion & Earth Month HTX

A clothing swap is a fun, alternative solution to thrift shopping or secondhand fashion that allows you to clean out the clothes you no longer wear and in return bring home new additions to your closet - all for free and hosted by Houston startup RESTATEMENT.

The event is Saturday, April 15, from noon to 5 pm, at Patterson Park. Click here to register.

April 17-18 — AI Powered Renewable Energy Workshop

AI Houston Institute of Rice University in partnership with Ion is getting together experts from academia and industry working on the application of artificial intelligence in solving some of the most complex challenges facing the Energy industry as it transitions into alternative sources of energy that are green and sustainable.

The event is Monday, April 17, to Tuesday, April 18, at the Ion. Click here to register.

April 19 — Investor Studio Series: Dream Big Ventures x Ion x Mendoza Ventures

Underrepresented founders face a lot of barriers, including rarely seeing VC dollars. However, Dream Big Ventures and Mendoza Ventures are looking to change those statistics to help diverse founders succeed. Join Dream Big Ventures Founder and CEO Staci LaToison, and Mendoza Ventures Co-Founders Senofer Mendoza and Adrian Mendoza, as they discuss the growth of women and Latinas in Fintech, AI, and Cybersecurity in this fireside chat.

The event is Wednesday, April 19, from 5 to 7 pm, at the Ion. Click here to register.

April 19 — The H. Albert Napier Rice Launch Challenge Championships

Join Liu Idea Lab for Innovation and Entrepreneurship and support Rice University student ventures at the H. Albert Napier Rice Launch Challenge (NRLC) Championships on Wednesday, April 19. Five student finalists will pitch their ventures to compete for the chance to win a share of $100,000 in equity-free funding.

The event is Wednesday, April 19, from 5:30 to 9 pm, at Rice University. Click here to register.

April 20 — Female Founders and Funders

Calling all rockstar female founders and investors in the Houston area. Mark your calendars for this month's Female Founders and Funders meetup. Coffee and breakfast is provided and the event is free to attend.

The event is Thursday, April 20, from 9 to 10 am, at Sesh Coworking. Click here to register.

Texas researchers name ancient beaver fossil after favorite Texas gas station

Beaver Country

The legend of a treasured gas station chain continues with a new chapter: a rediscovered beaver fossil is being named after Buc-ee’s.

The ancient animal was named Anchitheriomys buceei (A. buceei) by Steve May, a research associate at the University of Texas Jackson School of Geosciences and lead author of the Palaeontologia Electronica paper that describes the beaver.

A. buceei fossils were rediscovered by researchers in UT Austin’s collections and include fossils from six different Texas sites. May decided to name A. buceei after Buc-ee’s after spotting a “This is Beaver Country” billboard in 2020 that reminded him of the fossils he was studying at the time.

Though Buc-ee’s was founded in 1982, CEO Arch “Beaver” Alpin III said in a press release that his business’ history is longer than he thought, and that he may “need to rethink [their] beginnings.”

Occurrences of A. buceei can be found between 15 and 22 million years ago along the state’s gulf coast. At first glance, they don’t appear much different from current native Texas beavers. But according to the report’s co-author Matthew Brown, who is also the director of the Jackson School’s vertebrate paleontology collections, they are nearly 30 percent bigger than today’s beavers.

A partial skull fossil of the beaver was originally collected in 1941 by paleontologists. One of the original finders was Texas A&M University museum curator Curtis Hesse, who passed away four years later before he could name it a new species and publish his study.

More information about A. buceei can be found on UT Austin’s website.

------

This article originally ran on CultureMap.

5 most popular innovation stories in Houston this week

what's trending

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included Houston innovators to know, news from Rice University, and more.

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Gaurab Chakrabarti of Solugen, Sandy Guitar of HX Venture Fund, and Cameron Owen of rBIO. Photos courtesy

In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from synthetic biology to venture capital — recently making headlines in Houston innovation. Read more.

Annual student startup competition in Houston names teams for 2023

Here's what student teams from around the world were invited to compete in the Rice Business Plan Competition. Photo via rice.edu

Rice Alliance for Technology and Entrepreneurship has named the 42 student startup teams that were extended invitations to compete in the 23rd annual Rice Business Plan Competition

The 2023 startup competition will take place on Rice University campus May 11 to 13, and the teams representing 37 universities from six countries will pitch to investors, mentors, and other industry leaders for the chance to win funding and prizes. Last year's RBPC doled out nearly $2 million in investment prizes. Read more.

Med tech firm expands footprint, Houston innovator assumes new role, and more local innovation news

Proxima Clinical Research has announced an office expansion — and more Houston innovation news. Photo via Twitter

Houston's innovation ecosystem has had some big news this month, from new job titles for Houston innovators to expanding office space.

In this roundup of Houston startup and innovation news, a Houston organization expands its footprint in the TMC, Rice University opens applications for a cleantech accelerator, and more. Read more.

Houston biotech company expands leadership team

Cemvita has some news regarding its C-level execs. Photo courtesy of Cemvita

An innovative Houston startup that's working with energy companies to decarbonize their operations has made changes to its C-suite.

Tara Karimi, who co-founded Cemvita with her brother Moji, has transition to the company's chief science officer. Liz Dennett has been hired to Karimi's previous role of CTO. The changes enable Karimi to focus on leading Cemvita's scientific research and development efforts as well as participating in driving innovation within the biotech industry as a whole, according to the company's press release.

"I'm excited to take on the role of chief science officer at Cemvita and what it represents for our company's growth," says Karimi in the release. "As chief science officer, I look forward to shaping policy and driving the conversation around the role of biotechnology in the energy transition." Read more.

Rice University announces leader of new materials and nanotechnology institute

Lane Martin will lead the Rice Advanced Materials Institute beginning this summer. Photo courtesy of Rice

A recently established institute at Rice University has revealed its new leader.

The Rice Advanced Materials Institute has named Lane Martin as director. Martin will also serve as Welch Professor of Materials Science and NanoEngineering in the George R. Brown School of Engineering. He begins both roles on July 1.

“Lane is everything we expect our faculty to be — hard-working, committed to excellence, dedicated to students and collaborative across disciplines,” says Howard R. Hughes Provost Amy Dittmar in a news release. “I look forward to seeing Rice faculty and students reap the benefits of his leadership.” Read more.

View All Listings